Loading insider details...
Beta
Latest Form 4 (Jun 26, 2026): Grant/Award of 45,000 CNTX shares.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Company | Transaction | Shares | Value |
|---|---|---|---|---|
| Jun 26, 2026 | Context Therapeutics Inc. (CNTX) | Grant/Award | 45,000 | n/a |
| Apr 2, 2026 | Skye Bioscience, Inc. (SKYE) | Grant/Award | 75,000 | n/a |
| Feb 10, 2026 | Skye Bioscience, Inc. (SKYE) | Grant/Award | 35,000 | n/a |
| Jun 16, 2025 | SANGAMO THERAPEUTICS, INC (SGMO) | Grant/Award | 25,000 | n/a |
| Jun 12, 2025 | Context Therapeutics Inc. (CNTX) | Grant/Award | 123,500 | n/a |
| Feb 26, 2025 | Skye Bioscience, Inc. (SKYE) | Grant/Award | 35,000 | n/a |
| Nov 25, 2024 | Aurinia Pharmaceuticals Inc. (AUPH) | Grant/Award | 12,135 | n/a |
| Nov 13, 2024 | Aurinia Pharmaceuticals Inc. (AUPH) | Exercise/Conversion | 17,913 | n/a |
| Oct 31, 2024 | Skye Bioscience, Inc. (SKYE) | Grant/Award | 70,000 | n/a |
| Sep 5, 2024 | Context Therapeutics Inc. (CNTX) | Grant/Award | 19,315 | n/a |